Our Products

Afatinib Tablets 50 mg is a targeted therapy medication used primarily for the treatment of non-small cell lung cancer (NSCLC) with specific mutations in the epidermal growth factor receptor (EGFR), including exon 19 deletions and exon 21 L858R substitution mutations. It is also used in the treatment of other cancers with EGFR mutations. Afatinib works as a tyrosine kinase inhibitor by irreversibly blocking EGFR and other related receptors, inhibiting cancer cell growth and survival.

The 50 mg dosage is typically taken once daily, with or without food, as prescribed by a healthcare provider. Common side effects may include diarrhea, skin rash, mouth sores, fatigue, and changes in liver function. Regular monitoring of liver function, gastrointestinal symptoms, and skin reactions is important to ensure the drug’s effectiveness and minimize potential side effects. Dose adjustments may be necessary based on the patient’s response and tolerance to the medication.